ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ocrelizumab

Also written as “Ocrelizumab”, “CYB704” and “OCR SC”.

Its studies are mostly in Multiple Sclerosis · Arthritis, Rheumatoid · Multiple Sclerosis, Chronic Progressive · Multiple Sclerosis, Relapsing-Remitting · Lupus Nephritis, led by 5 companies.

Drug pageOcrelizumab: every studyMany companies study it; this page follows only the 42 they lead. All 56 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 5, 201842 company-led studies, 13 open or runningNext primary completion: Feb 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche3810 open or runningphase 4since Jul 5, 2018Feb 12, 2004Dec 31, 2027phase 3 · NCT05269004
Celltrionits history only11 open or runningphase 3since May 9, 2023May 9, 2023Feb 2027phase 3 · NCT05906992
Cinnagenits history only10 open or runningphase 3since Jun 27, 2021Jun 27, 2021none ahead
R-Pharmits history only11 open or runningphase 1since Apr 13, 2026Apr 13, 2026none ahead
Sandozits history only11 open or runningphase 3since Feb 19, 2025Feb 19, 2025none ahead

Also a collaborator on its studies: PPD Development, LP, Laboratory Corporation of America and Roche Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 22 studies since Feb 12, 2004.

  1. Jul 23, 2018Phase 3 study in Multiple SclerosisNCT03606460 · 141 enrolled · United States
  2. May 29, 2019Phase 1 study in Multiple SclerosisNCT03972306 · 134 enrolled · United States
  3. Jul 17, 2019Phase 3 study in Multiple Sclerosis, Chronic ProgressiveNCT04035005 · 1,013 enrolled · United States, Australia, Belgium and more
  4. Aug 14, 2019Phase 2 study in Multiple SclerosisNCT04075266 · 23 enrolled · United States, Italy, Poland
  5. May 1, 2020Phase 4 study in Multiple SclerosisNCT04377555 · 179 enrolled · United States, Kenya, Puerto Rico
  6. Sep 4, 20202 phase 3 studies in Multiple SclerosisNCT04544436, NCT04548999
  7. Aug 6, 20212 phase 4 studies in Multiple SclerosisNCT04998851, NCT04998812
  8. Nov 16, 2021Phase 3 study in Multiple Sclerosis, Relapsing-RemittingNCT05123703 · 188 enrolled · United States, Argentina, Australia and more
  9. Jan 12, 2022Phase 4 study in Multiple SclerosisNCT05208840 · Russian Federation
  10. Jan 27, 2022Phase 3 study in Multiple Sclerosis, Chronic ProgressiveNCT05232825 · 236 enrolled · United States, Brazil, Czechia and more
  11. Feb 11, 2022Phase 3 study in Multiple SclerosisNCT05269004 · 1,300 enrolled · United States, Argentina, Australia and more
  12. Nov 4, 2024Phase 3 study in Multiple SclerosisNCT06675955 · 500 planned · Bulgaria, France, Germany and more
  13. Mar 16, 2026Phase 4 study in Multiple Sclerosis, Chronic ProgressiveNCT07483450 · 60 enrolled · China
  14. May 20, 2026Phase 4 study in Multiple SclerosisNCT07609719 · 100 planned · United States, Puerto Rico

Ahead

  1. Dec 31, 2027Primary completion: phase 4 study in Multiple Sclerosis, Chronic ProgressiveNCT07483450
  2. Dec 31, 2027Primary completion: phase 3 study in Multiple SclerosisNCT05269004
  3. Feb 28, 2029Primary completion: phase 4 study in Multiple SclerosisNCT07609719
  4. Dec 31, 2029Primary completion: phase 3 study in Multiple SclerosisNCT06675955

TargetBeta

MS4A1 →read by rule
“A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity”NCIt, by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule

Other programs on MS4A1

ProgramCompanyFurthest phaseStudies
RituximabruleHoffmann-La Rochephase 4175
obinutuzumabruleHoffmann-La Rochephase 442
ublituximabruleTG Therapeuticsphase 323
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
Anti-CD20 Monoclonal Antibody MIL62rulebeijing-mabworks-biotech-co-ltdphase 310
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
zuberitamabrulebioray-pharmaceutical-co-ltdphase 33
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28

Studies

All 38 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07609719Multiple Sclerosis · United States, Puerto Rico4RecruitingFeb 28, 2029100
NCT07483450Multiple Sclerosis, Chronic Progressive · China4Active, not recruitingDec 31, 202760
NCT06675955Multiple Sclerosis · Bulgaria, France, Germany and more3RecruitingDec 31, 2029500
NCT05269004Multiple Sclerosis · United States, Argentina, Australia and more3Active, not recruitingDec 31, 20271,300
NCT05232825Multiple Sclerosis, Chronic Progressive · United States, Brazil, Czechia and more3CompletedMar 10, 2023236
NCT05208840Multiple Sclerosis · Russian Federation4WithdrawnJan 31, 20250
NCT05123703Multiple Sclerosis, Relapsing-Remitting · United States, Argentina, Australia and more3Active, not recruitingJun 9, 2025188
NCT04998851Multiple Sclerosis · United States, Spain, United Kingdom4CompletedMar 29, 202426
NCT04998812Multiple Sclerosis · United States, France, Germany and more4CompletedApr 8, 202470
NCT04548999Multiple Sclerosis · United States, Argentina, Belgium and more3Active, not recruitingJun 30, 2025769
NCT04544436Multiple Sclerosis · United States, Argentina, Australia and more3Active, not recruitingDec 19, 2024864
NCT04377555Multiple Sclerosis · United States, Kenya, Puerto Rico4CompletedDec 15, 2022179
NCT04075266Multiple Sclerosis · United States, Italy, Poland2Active, not recruitingOct 5, 202323
NCT04035005Multiple Sclerosis, Chronic Progressive · United States, Australia, Belgium and more3Active, not recruitingJan 15, 20251,013
NCT03972306Multiple Sclerosis · United States1CompletedJun 3, 2025134
NCT03606460Multiple Sclerosis · United States3CompletedMay 31, 2019141
NCT03589105Multiple Sclerosis · France4CompletedFeb 15, 2021423
NCT03599245Multiple Sclerosis · Argentina, Belgium, Brazil and more3CompletedJul 17, 20251,055
NCT03523858Multiple Sclerosis, Chronic Progressive · United States, Bosnia and Herzegovina, Brazil and more3Active, not recruitingOct 22, 2026927
NCT03085810Multiple Sclerosis, Relapsing-Remitting · United States, Argentina, Australia and more3TerminatedApr 27, 20231,225
NCT02861014Multiple Sclerosis, Relapsing-Remitting · Australia, Belgium, Czechia and more3CompletedOct 25, 2019681
NCT02723071Lymphoma, Non-Hodgkin · Australia, Canada, France and more2CompletedJan 200848
NCT02720120Arthritis, Rheumatoid · Australia, Belgium, Canada and more2TerminatedFeb 2013175
NCT02688985Multiple Sclerosis, Chronic Progressive · United States, Canada, Germany and more3CompletedApr 11, 2023131
NCT02637856Multiple Sclerosis, Relapsing-Remitting · United States, Canada3CompletedMay 3, 2019608
NCT01412333Relapsing Multiple Sclerosis · United States, Argentina, Belarus and more3CompletedMay 12, 2015835
NCT01247324Relapsing Multiple Sclerosis · United States, Argentina, Australia and more3CompletedApr 2, 2015821
NCT01194570Multiple Sclerosis, Chronic Progressive · United States, Australia, Austria and more3CompletedJul 23, 2015735
NCT00808210Arthritis, Rheumatoid · United States2TerminatedNov 14, 201228
NCT00779220Arthritis, Rheumatoid · Japan2TerminatedFeb 2010152
NCT00676715Multiple Sclerosis, Relapsing-Remitting · United States, Belgium, Bulgaria and more2CompletedMar 9, 2012220
NCT00673920Arthritis, Rheumatoid3TerminatedOct 26, 2009314
NCT00626197Lupus Nephritis3TerminatedOct 19, 2009381
NCT00539838Lupus Erythematosus, Systemic3TerminatedJul 12, 201133
NCT00485589Arthritis, Rheumatoid3TerminatedJan 29, 2010613
NCT00476996Arthritis, Rheumatoid · United States, Argentina, Australia and more3TerminatedJan 21, 2010836
NCT00406419Arthritis, Rheumatoid · United States3TerminatedOct 6, 20091,015
NCT00077870Arthritis, Rheumatoid2Completed237

How it is read

Names in the registry

  • “Ocrelizumab”, 36 entries
  • “ocrelizumab”, 2 entries
  • “CYB704”, 1 entry
  • “OCR SC”, 1 entry
  • “Ocrelizumab SC”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.